Bajaj HealthCare Limited share price

Bajaj HealthCare Limited, a pharmaceutical company, develops, manufactures, markets, and sells active pharmaceutical ingredient, intermediates, and finished dosage forms and nutraceuticals for pharmaceutical, nutraceuticals, and food industries in India and internationally. The company offers active pharmaceutical ingredient in various therapeutic categories, including anthelmintic, anti viral, anti coagulant, vitamin c, anti arthritis, atypical antipsychotic agent, anti convulsant, vasoprotective, disinfectant, anti asthamatic, neuro protective, anti histamine, iron chelator, vasoprotective, urinary tract infection, anti migraine, anti rheumatic, antibiotic, anti tussive, weight reducing, …Read more

Website NSE हिंदी में BSE

HealthcareDrug Manufacturers - Specialty & GenericNSE: BAJAJHCAREISIN INE411U01027

16 Oct 2026, 3:29 PM IST₹341.10▲ 2.30 (0.68%)

Market Cap₹ 1,148 Cr.
Current Price₹ 341.10
High / Low₹ 489 / 272
Stock P/E48.9
Book Value₹ 167
Dividend Yield0.44 %
ROCE8.4 %
ROE3.20 %
Face Value₹ 5.0

More figures (10)

EPS (TTM)₹ 6.98
Price / Book2.04
OPM12.7 %
Debt / Equity0.47
Sales growth (3Y)-3.2 %
Profit growth (3Y)-28.4 %
Promoter holding60.9 %
EV / EBITDA12.6
Beta0.29
All-time high₹ 745

Price chart

Price on NSE 50 DMA 200 DMA Volume

Returns	1M	3M	6M	YTD	1Y	3Y CAGR	5Y CAGR
BAJAJHCARE	+6.23%	-8.53%	-2.97%	-17.83%	-28.84%	-10.02%	—
Nifty 50	-0.31%	-3.85%	-4.34%	-11.42%	-9.53%	+5.46%	+4.76%

Price returns only (dividends not included). Prices from NSE via Yahoo Finance; may be delayed.

Quick take

Bajaj HealthCare Limited is in the Drug Manufacturers - Specialty & Generic industry (Healthcare), with a market value of ₹1,148 crore.
It trades at 48.9 times its last 12 months' earnings and 2.0 times book value.
Revenue grew -3.2% a year over the last 3 years, profit -28.4% a year.
Return on equity was 3.2% and return on capital employed 8.4% in the latest year.
Debt was 0.47 times shareholders' equity.
The share price is 30.2% below its 52-week high and down 28.8% over one year.
Promoters and insiders hold about 60.9%; institutions about 1.9%.

Pros

Institutional (FII + DII) holding has risen by 3.0 points over 3 years.

Cons

Return on equity has been low: -4.0% on average over the last 3 years.
Sales growth has been slow: -3.2% a year over the last 3 years.
Profit growth has been weak: -28.4% a year over the last 3 years.
Promoter holding has fallen by 9.10 points over 3 years, to 58.59%.
Trades at 48.9 times earnings, above its 3-year median of 29.5.

Pros and cons are generated automatically from the reported figures. They are observations, not a recommendation to buy or sell.

AI analysis

Plenitude AI reads the figures on this page and explains them in plain language. It does not say whether to buy or sell.

About Bajaj HealthCare Limited

Employees: 949
Head office: Thane

HealthcareDrug Manufacturers - Specialty & Generic

S.No.	Company	CMP ₹	P/E	Mar Cap ₹ Cr	Div Yld %	NP Qtr ₹ Cr	Qtr Profit Var %	Sales Qtr ₹ Cr	Qtr Sales Var %	ROCE %	ROE %	P/B	OPM %	Debt / Eq	Prom. Hold. %	Sales ₹ Cr	Sales Var 3Yrs %
1.	Bajaj HealthCare	341.10	48.9	1,148	0.44	14	15.75	166	11.28	8.4	3.2	2.04	12.7	0.47	60.91	611	-3.2
2.	Sun Pharmaceutical Industries	1,758.80	34.9	4,21,995	0.91	2,895	34.65	15,184	18.48	17.9	14.7	5.05	23.4	0.06	55.61	58,220	10.4
3.	Divi's Laboratories	9,144.50	83.0	2,42,758	0.33	902	36.25	3,080	19.15	19.0	16.2	14.48	28.4	0.00	52.00	10,476	11.0
4.	Torrent Pharmaceuticals	4,558.90	72.8	1,73,406	0.83	566	3.28	4,921	54.85	9.1	27.1	18.39	25.0	1.79	63.18	13,980	13.3
5.	Zydus Lifesciences	1,123.00	25.0	1,12,020	0.09	940	-19.74	7,802	24.03	19.0	19.7	4.17	21.7	0.46	75.18	26,720	16.5
6.	Laurus Labs	2,060.10	101.8	1,11,310	0.12	362	123.94	2,026	29.10	19.5	18.2	20.98	19.4	0.48	32.03	6,813	3.8
7.	Cipla	1,325.10	31.8	1,07,051	0.98	786	-39.18	7,119	2.33	14.9	11.8	3.11	17.5	0.02	31.13	28,163	7.2
8.	Dr. Reddy's Laboratories	1,233.00	31.0	1,02,707	0.66	444	-68.72	8,071	-5.56	14.2	12.1	2.68	14.9	0.21	30.14	33,593	11.0
9.	Aurobindo Pharma	1,666.90	26.0	95,910	0.00	1,033	14.29	9,106	8.65	13.5	9.9	2.56	15.6	0.21	54.79	33,385	10.7
10.	Mankind Pharma	2,275.50	46.0	93,988	0.00	574	29.12	4,031	12.89	13.7	12.5	5.76	19.9	0.39	75.39	14,278	17.7
	Median: 63 Co.	1,712.85	34.3	8,632	0.17	680	15.02	6,020	15.68	14.6	12.5	3.66	14.9	0.30	55.20	20,499	11.4

Companies in the same industry; the median covers every company in it that we hold figures for. Tap a heading to sort. Sorting and comparing are ways to explore data, not recommendations.

Quarterly Results

Standalone figures in ₹ crore

₹ Cr	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	130	101	109	134	132	133	123	154	149	148	161	153	166
YOY Sales Growth %				-15.49%	1.93%	31.50%	13.10%	15.36%	12.54%	11.14%	31.30%	-0.92%	11.28%
	108	82	89	118	108	109	101	143	124	121	131	130	137
Material Cost %	58%	44%	47%	63%	50%	50%	50%	61%	54%	50%	50%	53%	52%
Employee Cost %	8%	11%	11%	8%	10%	11%	12%	10%	10%	11%	10%	11%	11%
Other Expenses %	17%	26%	24%	18%	22%	21%	21%	21%	20%	21%	21%	21%	20%
Operating Profit	22	19	20	16	25	25	22	12	25	27	31	23	29
OPM %	17%	19%	18%	12%	19%	18%	18%	8%	16%	18%	19%	15%	17%
	0	1	1	6	1	3	2	14	1	2	2	3	1
Exceptional items				-44								-33
Interest	9	8	7	6	8	8	6	6	5	6	6	6	6
Depreciation	6	7	7	7	7	7	7	8	6	7	7	8	7
Profit before tax	7	5	6	-35	10	12	12	12	15	16	19	-21	16
	-2%	2%	13%		21%	33%	-28%	1%	16%	22%	16%		16%
Deferred tax	-0	0	1	-3	2	4	-3	0	2	4	3	-1	3
	-48	-3	-2	-30	7	9	12	11	12	11	16	-23	14
YOY Profit Growth %				-932.99%					65.92%	17.38%	33.72%	-304.43%	15.75%
EPS in Rs	-17.46	-1.25	-0.80	-10.84	2.59	3.36	3.65	3.54	3.74	3.53	4.96	-7.16	4.07
Raw filing

Source: the company's results filed with NSE, as reported. Tap a row marked + for its breakdown. Latest quarter on the right.

Profit & Loss

Standalone figures in ₹ crore

₹ Cr	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
	680	673	473	543	611	628
YOY Sales Growth %		-0.97%	-29.69%	14.61%	12.61%
	561	566	397	460	506	519
Material Cost %	73%	73%	54%	53%	52%	51%
Employee Cost %	6%	7%	9%	11%	10%	10%
Other Expenses %	4%	4%	21%	22%	21%	21%
Operating Profit	119	107	76	82	105	109
OPM %	17%	16%	16%	15%	17%	17%
	1	2	9	19	7	7
Exceptional items			-44		-33	-33
Interest	13	23	30	28	22	23
Depreciation	18	27	28	28	28	29
Profit before tax	90	58	-17	46	29	31
	20%	26%		7%	26%	25%
Current tax	23	16
Deferred tax	-4	-1	-2	3	8
	71	43	-84	39	16	18
YOY Profit Growth %		-39.73%	-294.76%		-60.08%
EPS in Rs	25.87	15.59	-30.36	13.29	4.98	5.40
Dividend Payout %		10%		7%	20%

Compounded Sales Growth

3 Years:: -3%
TTM:: 12%

Compounded Profit Growth

3 Years:: -28%
TTM:: -60%

Stock Price CAGR

3 Years:: -10%
1 Year:: -29%

Return on Equity

4 Years:: 0%
Last Year:: 3%

Financial years ending March; TTM = the last four quarters. Source: the company's results filed with NSE, as reported. Tap a row marked + for its breakdown. Dividend payout = dividends paid in the year ÷ net profit.

Balance Sheet

Consolidated figures in ₹ crore, as at 31 March

₹ Cr	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	14	14	16	17
Reserves	354	265	450	516
	415	333	223	249
Long term borrowings	94	39	65	48
Short term borrowings	321	293	158	186
	115	154	144	141
Trade payables	85	89	100	115
Current liabilities	434	441	297	323
Total Liabilities	898	765	833	923
	386	258	240	255
Gross block	545	428	438	478
Accumulated depreciation	159	170	197	223
Goodwill & intangibles	1	2	1	1
CWIP	20	5	3	8
	491	503	589	660
Inventories	209	144	162	216
Trade receivables	194	180	252	234
Cash & equivalents	18	2	3	37
Current assets	500	480	564	639
Total Assets	898	765	833	923

Source: Yahoo Finance (compiled from the annual reports). Tap a row marked + for its breakdown.

Cash Flows

Consolidated figures in ₹ crore, financial years ending March

₹ Cr	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	-22	92	22	58
Profit for the year	43	-84	39	16
Working capital changes	-125	39	-62	-48
Direct taxes paid	-12	-13	-5	2
	-93	-11	-15	-48
Fixed assets purchased	-94	-30	-12	-43
Fixed assets sold	1	11	0	3
Investments purchased			-4	-2
Investments sold		7		2
	131	-97	-6	24
Proceeds from borrowings		26	45	1
Repayment of borrowings		-44	-43	-31
Interest paid	-23	-42	-28	-22
Dividends paid	-4	-3	-3	-3
Net Cash Flow	16	-16	0	35
Free Cash Flow	-116	62	10	15

Free cash flow = cash from operations − capital expenditure. Source: Yahoo Finance.

Ratios

Ratio	Mar 2023	Mar 2024	Mar 2025	Mar 2026
ROE	11.7%	-25.9%	10.6%	3.2%
ROCE	20.4%	4.0%	13.3%	8.4%
Operating margin	14.6%	10.3%	10.1%	12.7%
Net margin	6.7%	-17.7%	7.3%	2.6%
Debt / equity	1.13	1.20	0.48	0.47
Current ratio	1.15	1.09	1.90	1.98
Debtor days	110	139	169	140
Inventory days	197	203	190	236
Days payable	80	126	117	126
Cash conversion cycle	227	216	242	250
Working capital days	38	30	179	189

Computed from the reported statements: ROE on average equity; ROCE = EBIT / (total assets − current liabilities). Debtor days = receivables ÷ sales × 365; inventory and payable days use cost of goods sold; cash conversion cycle = debtor + inventory − payable days; working capital days = (current assets − current liabilities) ÷ sales × 365.

Shareholding Pattern

Numbers in percentages · as filed with NSE each quarter

Promoters 58.59%
FIIs 2.19%
DIIs 1.92%
Public 37.30%

%	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Promoters	67.69%	67.73%	67.73%	67.73%	59.19%	59.19%	59.19%	59.19%	59.19%	59.19%	58.29%	58.59%
	0.66%	0.74%	0.53%	0.01%	1.07%	1.01%	1.05%	1.09%	1.12%	1.18%	1.98%	2.19%
Foreign portfolio investors (Cat. I)	0.66%	0.74%	0.53%		0.88%	1.01%	1.05%	1.09%	1.12%	1.18%	1.45%	1.61%
Foreign portfolio investors (Cat. II)					0.19%						0.53%	0.58%
	0.44%	0.48%	0.44%		1.97%	2.36%	2.52%	3.16%	3.00%	2.96%	2.91%	1.92%
Mutual funds					1.31%	1.64%	1.64%	1.66%	1.66%	1.66%	1.69%	1.69%
Alternative investment funds	0.43%	0.48%	0.43%		0.66%	0.72%	0.88%	1.50%	1.33%	1.30%	1.22%	0.23%
	31.22%	31.06%	31.30%	32.26%	37.78%	37.45%	37.24%	36.56%	36.70%	36.67%	36.82%	37.30%
Retail (up to ₹2 lakh)	15.00%	16.50%	18.38%	18.68%	18.29%	18.12%	18.40%	18.64%	20.29%	21.07%	20.58%	22.63%
HNIs (above ₹2 lakh)	3.43%	2.95%	1.53%	1.50%	7.22%	8.82%	8.32%	8.00%	5.95%	5.55%	7.91%	7.19%
NRIs	0.98%	0.63%	0.77%	0.82%	1.00%	1.20%	1.33%	1.12%	1.67%	1.52%	1.34%	1.41%
Bodies corporate	10.71%	9.97%	9.59%	10.10%	7.13%	6.96%	6.89%	6.46%	6.10%	5.85%	4.41%	3.67%
No. of Shareholders	28,008	29,626	32,712	32,397	31,995	32,672	35,710	35,980	38,576	37,953	38,158	41,310

Source: shareholding patterns filed by the company with NSE. Public = non-institutional holders. Tap a row marked + for its breakdown.

Mutual funds & institutions holding Bajaj HealthCare

Holder (above 1%)	Stake
HDFC Pharma and Healthcare FundMutual fund	1.69%

As named in the shareholding pattern for Jun 2026 filed with NSE; mutual funds together hold 1.69% of the company. Shareholders below 1% are not named in the filing.

Documents

Announcements

All announcements on NSE →

Annual reports

Credit ratings

Concalls & investor meets

Filings made by the company with NSE; documents open on NSE's website.

Key dates

Ex-dividend date: 11 Sep 2026
Latest quarter: 30 Jun 2026
Financial year end: 31 Mar 2026

Trade with our broking desk

Open a trading & demat account through Parshvanath Investments, Authorised Person of Master Capital Services Ltd (SEBI Reg. INZ000210539; NSE AP0153037862, BSE AP01095201177059). Execution and service only: no tips or research.

Open an account How it works

Latest news

In the news

From the company (NSE)

Headlines from news publishers (via Google News) and the filings of the company with NSE; they open on the source website. Headlines with price targets or buy/sell calls are left out. News is for information only and is not a recommendation.

Questions about Bajaj HealthCare Limited

What is the share price of Bajaj HealthCare Limited today?

Bajaj HealthCare Limited (BAJAJHCARE) last traded at ₹341.10 on NSE (16 Oct 2026, 3:29 PM IST). Prices may be delayed.

What is the market cap of Bajaj HealthCare Limited?

About ₹1,148 crore at the latest price.

What is the P/E ratio of Bajaj HealthCare Limited?

About 48.9 times its earnings over the last 12 months.

Is Bajaj HealthCare Limited a good investment?

We do not give views on individual shares. Whether any share suits you depends on your goals, time horizon and risk appetite; for long-term goals, a diversified mutual fund is often a simpler way to own shares. Investments in securities markets are subject to market risks.

How can I buy Bajaj HealthCare Limited shares?

You need a trading and demat account with a SEBI-registered stock broker. We can help you open one through Parshvanath Investments, an Authorised Person of Master Capital Services Ltd (SEBI Reg. INZ000210539). We provide execution and account service only, not tips or research.

Important. Prices from NSE via Yahoo Finance. Quarterly and annual results, shareholding and documents are taken from the filings the company made with NSE; balance sheet, cash flow and valuation figures are compiled by Yahoo Finance; ratios are computed by us from them. Figures may be delayed or revised. This page is for information only: it is not research, a recommendation or an offer to buy or sell any security. Investments in securities markets are subject to market risks; read all related documents carefully before investing. Plenitude Connect Private Limited is an AMFI-registered Mutual Fund Distributor (ARN-130934); share broking is offered through Parshvanath Investments, Authorised Person of Master Capital Services Ltd (SEBI Reg. INZ000210539).

Talk to us

Have a question about this topic?

Tell us a little about your situation and an expert will call you back, usually within 2 hours on business days.

Get in touch

We typically respond within 2 hours on business days.

Call us

CA Amit Kumar Jain+91 93522 44475 Arihant Jain+91 80056 49698 Poornima Jain+91 92525 44475

Email ussupport@plenitude.co.in

WhatsAppChat with an expert

Visit us5C, Laxmi Colony, Near Bohra Ji Ka Bagh, Opp. Laxmi Mandir Cinema, Tonk Road, Jaipur, Rajasthan 302015

Mon–Sat · 10:00 AM – 7:00 PM IST

In your free consultation

A health check of your current investments
A goal-based plan for retirement, education or a home
Ways to save tax that fit your situation
Clear next steps, with zero pressure to invest

2,000+Investors

₹250 Cr+Client assets

15+ yrsExperience

AMFI Registered Mutual Fund Distributor · ARN-130934

Experts are available Mon–Sat, 10 AM – 7 PM

Book your free wealth consultation

100% free
No obligation
Reply within 2 hours

First name *

Last name *

Email *

Phone *

+91

I'm interested in *

Best day for a call

Preferred time

How can we help? (optional)

Upload your portfolio (optional, get a free expert review)Attach your portfolio statement · PDF, Excel or CSV (e.g. CAS), max 10 MB

I consent to being contacted by Plenitude Connect about financial services. My data will be handled as per the Privacy Policy.

Join 2,000+ investors who plan with Plenitude

Your details are private and never shared.